tbuckley/cabot-search huggingface dataset:
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Authors: Mehra Golshan, Sibylle Loibl, Stephanie M. Wong, Jens Bodo Huober, Joyce O’Shaughnessy, Hope S. Rugo, Norman Wolmark, Mark D. McKee, David Maag, Danielle M. Sullivan, Otto Metzger-Filho, Gunter Von Minckwitz, Charles E. Geyer, William M. Sikov, Michael Untch
Journal: JAMA Surgery (2020)

Neoadjuvant systemic therapy (NST) is often administered to enable breast-conserving therapy (BCT) in stages II to III breast cancer.To prospectively evaluate the role of NST in conversion from BCT ineligibility to BCT eligibility and to assess the association of response to NST, germline BRCA (gBRCA) status, and region of treatment with surgical choice in women with triple-negative breast cancer (TNBC).This prespecified secondary analysis of a multicentered, phase 3, double-blind, randomized clinical trial (BrighTNess) enrolled 634 eligible women across 145 centers in 15 countries in North America, Europe, and Asia. Women with operable, clinical stages II to III TNBC who underwent gBRCA mutation testing before initiating NST were eligible to participate. Data were collected from April 1, 2014, to December 8, 2016. This preplanned analysis was performed from January 5, 2018, to October 28, 2019.Study participants were randomized to receive 12 weeks of weekly paclitaxel alone or with the addition of carboplatin and/or veliparib, followed by 4 cycles of doxorubicin hydrochloride and cyclophosphamide.Surgeons assessed BCT candidacy by clinical and radiographic criteria before and after NST. Surgical choices and whether BCT eligibility was associated with the likelihood of pathologic complete response were then analyzed.Among the 634 randomized patients (median age, 51 [range, 22-78] years), pre- and post-NST assessments were available for 604 patients. Of 141 patients deemed BCT ineligible at baseline, 75 (53.2%) converted to BCT eligible. Overall, 342 (68.1%) of 502 patients deemed BCT eligible after NST underwent BCT, including 42 (56.0%) of the 75 who converted to BCT eligible. Patients treated in Europe and Asia were more likely to undergo BCT (odds ratio, 2.66; 95% CI, 1.84-3.84) compared with those treated in North America. Among patients without gBRCA mutation undergoing mastectomy, those treated in North America were more likely to undergo contralateral prophylactic mastectomy (57 of 81 [70.4%] vs 6 of 30 [20.0%]; P < .001). Rates of pathologic complete response were similar between patients deemed BCT eligible at baseline and those who were BCT ineligible but converted to BCT eligibility after NST (55.3 [235 of 425] vs 49.3% [37 of 75]; P = .38).This prospective analysis of NST and BCT eligibility in TNBC demonstrates a conversion from BCT ineligibility to BCT eligibility of 53.2%. Lower BCT rates among eligible patients and higher bilateral mastectomy rates among patients without gBRCA mutation in North America merit investigation.ClinicalTrials.gov identifier: NCT02032277.
The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)
Authors: Britton Trabert, Shelley S. Tworoger, Katie M. O'Brien, Mary K. Townsend, Renée T. Fortner, Edwin S. Iversen, Patricia Hartge, Emily White, Pilar Amiano, Alan A. Arslan, Leslie Bernstein, Louise A. Brinton, Julie E. Buring, Laure Dossus, Gary E. Fraser, Mia M. Gaudet, Graham G. Giles, Inger T. Gram, Holly R. Harris, Judith Hoffman Bolton, Annika Idahl, Michael E. Jones, Rudolf Kaaks, Victoria A. Kirsh, Synnove F. Knutsen, Marina Kvaskoff, James V. Lacey, I-Min Lee, Roger L. Milne, N. Charlotte Onland-Moret, Kim Overvad, Alpa V. Patel, Ulrike Peters, Jenny N. Poynter, Elio Riboli, Kim Robien, Thomas E. Rohan, Dale P. Sandler, Catherine Schairer, Leo J. Schouten, Veronica W. Setiawan, Anthony J. Swerdlow, Ruth C. Travis, Antonia Trichopoulou, Piet A. van den Brandt, Kala Visvanathan, Lynne R. Wilkens, Alicja Wolk, Anne Zeleniuch-Jacquotte, Nicolas Wentzensen
Journal: Cancer Research (2020)

Repeated exposure to the acute proinflammatory environment that follows ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may increase ovarian cancer risk. To address this, analyses included individual-level data from 558,709 naturally menopausal women across 20 prospective cohorts, among whom 3,246 developed invasive epithelial ovarian cancer (2,045 serous, 319 endometrioid, 184 mucinous, 121 clear cell, 577 other/unknown). Cox models were used to estimate multivariable-adjusted HRs between lifetime ovulatory cycles (LOC) and its components and ovarian cancer risk overall and by histotype. Women in the 90th percentile of LOC (>514 cycles) were almost twice as likely to be diagnosed with ovarian cancer than women in the 10th percentile (<294) [HR (95% confidence interval): 1.92 (1.60-2.30)]. Risk increased 14% per 5-year increase in LOC (60 cycles) [(1.10-1.17)]; this association remained after adjustment for LOC components: number of pregnancies and oral contraceptive use [1.08 (1.04-1.12)]. The association varied by histotype, with increased risk of serous [1.13 (1.09-1.17)], endometrioid [1.20 (1.10-1.32)], and clear cell [1.37 (1.18-1.58)], but not mucinous [0.99 (0.88-1.10), P-heterogeneity = 0.01] tumors. Heterogeneity across histotypes was reduced [P-heterogeneity = 0.15] with adjustment for LOC components [1.08 serous, 1.11 endometrioid, 1.26 clear cell, 0.94 mucinous]. Although the 10-year absolute risk of ovarian cancer is small, it roughly doubles as the number of LOC rises from approximately 300 to 500. The consistency and linearity of effects strongly support the hypothesis that each ovulation leads to small increases in the risk of most ovarian cancers, a risk that cumulates through life, suggesting this as an important area for identifying intervention strategies. SIGNIFICANCE: Although ovarian cancer is rare, risk of most ovarian cancers doubles as the number of lifetime ovulatory cycles increases from approximately 300 to 500. Thus, identifying an important area for cancer prevention research.
Efficacy and Safety of Ipilimumab Reinduction Therapy Patients with Pretreated Advanced Melanoma Participating in an Expanded Access Programme (EAP) in Italy
Authors: J. Pigozzo, L. Calabrò, P.A. Ascierto, F. De Galitiis, P.F. Ferrucci, P. Queirolo, M.G. Bernengo, M. Aglietta, M. Mandala, M. Del Vecchio
Journal: Annals of Oncology (2012)
A Phase I Study of the Combination of RO4929097 (RO) And Cediranib (CD) in Patients with Advanced Solid Tumors (PJC-004/NCI 8503)
Authors: S. Sahebjam, P. Bedard, V. Castonguay, H. Chen, S.P. Ivy, A.M. Oza, E.X. Chen, H.W. Hirte, L. Siu, S.J. Hotte
Journal: Annals of Oncology (2012)
To Clarify the Difference between the Treatment by Oncologist and Palliative Physicians: A Multicenter Retrospective Study, HOME1202
Authors: Y. Komatsu, T. Tamaki, A. Kumagai, Y. Narita, K. Katayama, H. Isobe, M. Nakamura, Y. Goda, Y. Takahashi, Y. Iwanami, Y. Suzuki, K. Tanaka, S. Ozaki
Journal: Annals of Oncology (2012)
Updated Survival, Quality of Life (QOL), and Safety Data of Radium-223 Chloride (RA-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases from the Phase 3 Double-Blind, Randomized, Multinational Study (ALSYMPCA)
Authors: C. Parker, R.E. Coleman, S. Nilsson, N. Vogelzang, A.J. Lloyd, K. Staudacher, R. van Gool, A.O. Sartor
Journal: Annals of Oncology (2012)
P-0211 The Prognostic Significance of Tumor Egfr Expression After Neoadjuvant Chemoradiation in Patients With Rectal Adenocarcinoma
Authors: Igor Richter, Veronika Sitorová, Ales Ryska, Josef Dvorak, Igor Sirak, Jana Hatlova, Ferko Alexander, Bohuslav Melichar, Jiri Petera
Journal: Annals of Oncology (2012)
Corrections to “Capturing intra-tumor genetic heterogeneity byde novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle”
Authors: L De Mattos-Arruda, B. Weigelt, J. Cortes, H.H. Won, C.K.Y. Ng, P. Nuciforo, F.-C. Bidard, C. Aura, C. Saura, V. Peg, S. Piscuoglio, M. Oliveira, Y. Smolders, P. Patel, L. Norton, J. Tabernero, M.F. Berger, J. Seoane, J.S. Reis-Filho
Journal: Annals of Oncology (2018)

Ann Oncol 2014; 25: 1729–1735 (doi: 10.1093/annonc/mdu239) In the original article, the following funding information was omitted: ‘This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748’. This has now been added. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principleAnnals of OncologyVol. 25Issue 9PreviewPlasma-derived cell-free tumor DNA (ctDNA) constitutes a potential surrogate for tumor DNA obtained from tissue biopsies. We posit that massively parallel sequencing (MPS) analysis of ctDNA may help define the repertoire of mutations in breast cancer and monitor tumor somatic alterations during the course of targeted therapy. Full-Text PDF Open Archive
Exploring choroidal angioarchitecture in health and disease using choroidal vascularity index
Authors: Rupesh Agrawal, Jianbin Ding, Parveen Sen, Andres Rousselot, Amy Chan, Lisa Nivison-Smith, Xin Wei, Sarakshi Mahajan, Ramasamy Kim, Chitaranjan Mishra, Manisha Agarwal, Min Hee Suh, Saurabh Luthra, Marion R. Munk, Carol Y. Cheung, Vishali Gupta
Journal: Progress in Retinal and Eye Research (2020)
Ipilimumab in Older Patients: Spanish Melanoma Multidisciplinary Group (GEM) Experience in the Expanded Access Programme
Authors: J.A. Lopez Martin, M. Gonzalez Cao, M. Sereno, J. Mayordomo, M. Hidalgo, B. Campos, D. Cumplido, F. Zambrana, J. Medina, A. Berrocal
Journal: Annals of Oncology (2012)
Effective Management of Chemotherapy-Induced Anaemia in Clinical Practice using Darbepoetin Alfa: Final Data from the Correct II Study
Authors: H.T. Steinmetz, O. Lange, U. Vehling-Kaiser, M. Kindler, U. Söling, A. Kuhn, E. Hellebrand, J. Eggert
Journal: Annals of Oncology (2012)
A Prospective, Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors
Authors: S. Park, K. Park, M. Ahn, J.S. Ahn, J.-M. Sun, H.K. Ahn, S.J. Lee, C.H. Maeng, D.W. Hwang
Journal: Annals of Oncology (2012)
TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2
Authors: You Shuai, Zhonghua Ma, Weitao Liu, Tao Yu, Changsheng Yan, Hua Jiang, Shengwang Tian, Tongpeng Xu, Yongqian Shu
Journal: Molecular Cancer (2020)

Gastric cancer (GC) is the third leading cause of cancer-related mortality globally. Long noncoding RNAs (lncRNAs) are dysregulated in obvious malignancies including GC and exploring the regulatory mechanisms underlying their expression is an attractive research area. However, these molecular mechanisms require further clarification, especially upstream mechanisms. LncRNA MNX1-AS1 expression in GC tissue samples was investigated via microarray analysis and further determined in a cohort of GC tissues via quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays. Cell proliferation and flow cytometry assays were performed to confirm the roles of MNX1-AS1 in GC proliferation, cell cycle regulation, and apoptosis. The influence of MNX1-AS1 on GC cell migration and invasion was explored with Transwell assays. A xenograft tumour model was established to verify the effects of MNX1-AS1 on in vivo tumourigenesis. The TEAD4-involved upstream regulatory mechanism of MNX1-AS1 was explored through ChIP and luciferase reporter assays. The mechanistic model of MNX1-AS1 in regulating gene expression was further detected by subcellular fractionation, FISH, RIP, ChIP and luciferase reporter assays. It was found that MNX1-AS1 displayed obvious upregulation in GC tissue samples and cell lines, and ectopic expression of MNX1-AS1 predicted poor clinical outcomes for patients with GC. Overexpressed MNX1-AS1 expression promoted proliferation, migration and invasion of GC cells markedly, whereas decreased MNX1-AS1 expression elicited the opposite effects. Consistent with the in vitro results, MNX1-AS1 depletion effectively inhibited the growth of xenograft tumour in vivo. Mechanistically, TEAD4 directly bound the promoter region of MNX1-AS1 and stimulated the transcription of MNX1-AS1. Furthermore, MNX1-AS1 can sponge miR-6785-5p to upregulate the expression of BCL2 in GC cells. Meanwhile, MNX1-AS1 suppressed the transcription of BTG2 by recruiting polycomb repressive complex 2 to BTG2 promoter regions. Our findings demonstrate that MNX1-AS1 may be able to serve as a prognostic indicator in GC patients and that TEAD4-activatd MNX1-AS1 can promote GC progression through EZH2/BTG2 and miR-6785-5p/BCL2 axes, implicating it as a novel and potent target for the treatment of GC.
The pursuit of euthymia
Authors: Giovanni A. Fava, Jenny Guidi
Journal: World Psychiatry (2020)

Psychiatrists often consider the positive characteristics displayed by a patient in their clinical judgment, yet current assessment and treatment strategies are shifted on the side of psychological dysfunction. Euthymia is a transdiagnostic construct referring to the presence of positive affects and psychological well‐being, i.e., balance and integration of psychic forces (flexibility), a unifying outlook on life which guides actions and feelings for shaping future accordingly (consistency), and resistance to stress (resilience and tolerance to anxiety or frustration). There is increasing evidence that the evaluation of euthymia and its components has major clinical implications. Specific instruments (clinical interviews and questionnaires) may be included in a clinimetric assessment strategy encompassing macro‐analysis and staging. The pursuit of euthymia cannot be conceived as a therapeutic intervention for specific mental disorders, but as a transdiagnostic strategy to be incorporated in an individualized therapeutic plan. A number of psychotherapeutic techniques aiming to enhance positive affects and psychological well‐being (such as well‐being therapy, mindfulness‐based cognitive therapy, and acceptance and commitment therapy) have been developed and validated in randomized controlled clinical trials. The findings indicate that flourishing and resilience can be promoted by specific interventions leading to a positive evaluation of one's self, a sense of continuing growth and development, the belief that life is purposeful and meaningful, satisfaction with one's relations with others, the capacity to manage effectively one's life, and a sense of self‐determination.
Diverse Mechanisms of Sound Frequency Discrimination in the Vertebrate Cochlea
Authors: Robert Fettiplace
Journal: Trends in Neurosciences (2020)

Discrimination of different sound frequencies is pivotal to recognizing and localizing friend and foe. Here, I review the various hair cell-tuning mechanisms used among vertebrates. Electrical resonance, filtering of the receptor potential by voltage-dependent ion channels, is ubiquitous in all non-mammals, but has an upper limit of ~1 kHz. The frequency range is extended by mechanical resonance of the hair bundles in frogs and lizards, but may need active hair-bundle motion to achieve sharp tuning up to 5 kHz. Tuning in mammals uses somatic motility of outer hair cells, underpinned by the membrane protein prestin, to expand the frequency range. The bird cochlea may also use prestin at high frequencies, but hair cells <1 kHz show electrical resonance.
Gut microbiota profiles in critically ill patients, potential biomarkers and risk variables for sepsis
Authors: Gloria M. Agudelo-Ochoa, Beatriz E. Valdés-Duque, Nubia A. Giraldo-Giraldo, Ana M. Jaillier-Ramírez, Adriana Giraldo-Villa, Irene Acevedo-Castaño, Mónica A. Yepes-Molina, Janeth Barbosa-Barbosa, Alfonso Benítez-Paéz
Journal: Gut Microbes (2020)

Critically ill patients are physiologically unstable and recent studies indicate that the intestinal microbiota could be involved in the health decline of such patients during ICU stays. This study aims to assess the intestinal microbiota in critically ill patients with and without sepsis and to determine its impact on outcome variables, such as medical complications, ICU stay time, and mortality. A multi-center study was conducted with a total of 250 peri-rectal swabs obtained from 155 patients upon admission and during ICU stays. Intestinal microbiota was assessed by sequencing the V3-V4 hypervariable regions of the 16S rRNA gene. Linear mixed models were used to integrate microbiota data with more than 40 clinical and demographic variables to detect covariates and minimize the effect of confounding factors. We found that the microbiota of ICU patients with sepsis has an increased abundance of microbes tightly associated with inflammation, such as Parabacteroides, Fusobacterium and Bilophila species. Female sex and aging would represent an increased risk for sepsis possibly because of some of their microbiota features. We also evidenced a remarkable loss of microbial diversity, during the ICU stay. Concomitantly, we detected that the abundance of pathogenic species, such as Enterococcus spp., was differentially increased in sepsis patients who died, indicating these species as potential biomarkers for monitoring during ICU stay. We concluded that particular intestinal microbiota signatures could predict sepsis development in ICU patients. We propose potential biomarkers for evaluation in the clinical management of ICU patients.
Immunohistochemical Ki67 Labeling Index has a Similar Proliferation Predictive Power as Various First-Generation Gene Signatures in Breast Cancer
Authors: N. Niikura, T. Iwamoto, S. Masuda, N. Kumaki, M. Shirane, K. Mori, T. Okamura, Y. Saito, Y. Suzuki, Y. Tokuda
Journal: Annals of Oncology (2012)
Initial Standardized Uptake Value (ISUV) of 18F-Fluorodeoxyglucose PET can Customize Treatment of Esophageal Adenocarcinoma (EAC) Patients who Achieve Clinical Complete Response (CCR) after Chemoradiation
Authors: A. Suzuki, L. Xiao, T. Taketa, M. Blum, J. Welsh, S. Lin, M. Bhutani, J. Lee, D. Rice, D. Maru, J. Erasmus, W. Hofstetter, S. Stephen, H. Onodera, J. Ajani
Journal: Annals of Oncology (2012)
A Pilot Trial of Gemcitabine in Combination with Capecitabine or Erlotinib Compared to Gemcitabine alone in Patients with advanced Pancreatic Cancer
Authors: J.Y. Cho, J.Y. Lim, S.J. Lee, D.K. Lee, J.S. Park, D.S. Yoon, Y.H. Min
Journal: Annals of Oncology (2012)
Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors
Authors: Y.Y. Janjigian, E.F. Smit, L. Horn, H.J.M. Groen, D.R. Camidge, S. Gettinger, Y. Fu, L.J. Denis, V. Miller, W. Pao
Journal: Annals of Oncology (2012)
The EVALI and Youth Vaping Epidemics — Implications for Public Health
Authors: Brian A. King, Christopher M. Jones, Grant T. Baldwin, Peter A. Briss
Journal: New England Journal of Medicine (2020)

The EVALI and Youth Vaping Epidemics Interventions aimed at curbing two related U.S. epidemics connected with vaping — an outbreak of lung injuries and a continued surge in use by young people — sh...
Predictors of Home Death in Patients with Terminal Lung Cancer: A Single-Centre Retrospective Study for the Regional Alliance
Authors: T. Hirashima, M. Higashiguchi, S. Goya, N. Okamoto, Y. Hashiguchi, K. Iwata, Y. Nakamura, Y. Omori, H. Hino, M. Saijo, H. Suzuki, M. Tamiya, N. Morishita, T. Shiroyama, I. Kawase
Journal: Annals of Oncology (2012)
Response to: ‘Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study’ by Lee
Authors: Jun Inamo
Journal: Annals of the Rheumatic Diseases (2020)

I am grateful to Dr Young Ho Lee1 for response to my article.2 Although my study demonstrated non-causal association between gut microbiome and the risk of rheumatoid arthritis (RA), the author demonstrated significant association between them.

First, the reason why different conclusions were drawn from two studies is that I extracted only ‘Gut microbiota (bacterial taxa) (unit decrease)’ from variables of exposures in harmonised dataset before conducting Mendelian randomisation (MR) (R script is …
Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes: Erratum
Authors: Esther Llop, Montserrat Ferrer-Batallé, Sílvia Barrabés, Pedro Enrique Guerrero, Manel Ramírez, Radka Saldova, Pauline M. Rudd, Rosa N. Aleixandre, Josep Comet, Rafael de Llorens, Rosa Peracaula
Journal: Theranostics (2017)

[This corrects the article DOI: 10.7150/thno.15226.].
Gemcitabine, Oxaliplatin, and Paclitaxel (GOT) on a 2-Weekly Schedule in Patients (PTS) with Refractory Germ Cell Carcinoma: A Phase II Study Conducted at the University of Southern California
Authors: D.I. Quinn, O. Hamid, D. Tsao-Wei, J. Hu, J. Pinski, A. Schuckman, S. Daneshmand, S. Groshen, D. Raghavan, C. Korn, K. Massopust, C. Ketchens, A.M. Aparicio, T.B. Dorff
Journal: Annals of Oncology (2012)
On‐Demand Printing of Wearable Thermotherapy Pad
Authors: Dong‐Il Moon, Gintarė Plečkaitytė, Taejun Choi, Myeong‐Lok Seol, Beomseok Kim, Dongil Lee, Jin‐Woo Han, M. Meyyappan
Journal: Advanced Healthcare Materials (2020)

Abstract Thermotherapy is an effective method for pain relief, recovery from injury, and general healthcare. The ordinary heat pad used for thermotherapy at home is not usually tailored to the individual but supplied in a few different pre‐fixed sizes and shapes for mass marketing. A customized wearable heat pad often requires expert support. Herein, an instant, custom‐fit, and on‐demand heat pad for thermotherapy is demonstrated. The heater is directly printed using silver nanoparticle ink on an off‐the‐shelf medical grade tape by inkjet technology. By coating the tape with silica nanoparticles as ink‐absorbing layer and chloride ions as chemical sintering agent, stable heater patterns are printed without the need for subsequent high temperature sintering process. A 3D scanner is used to acquire body information, and a customized heater is produced using the information. The printed heat pad is attached to the shoulder and the effect of thermotherapy is verified objectively through electroencephalography and subjectively through survey. This printed heat pad produced by simple and low‐cost fabrication provides wearable medical devices for personal thermotherapy.